Cybin D/B/A Helus Pharma (HELP) News
Track canonical SquawkNews coverage tagged to HELP, Cybin D/B/A Helus Pharma. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 32 indexed stories across 20 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
By Puyaan Singh and Kamal ChoudhuryThe U.S. FDA is holding a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs, the latest step in a months-long push by President Donald Tr
REGULATION | Sep 14, 2026, 07:30 PM UTC
L
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of Sept. 10, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares
EARNINGS | Sep 10, 2026, 12:25 PM UTC
L
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT.NEW YORK and TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma NASDAQ:HELP (Cboe CA: HELP) (the “Company” or
EQUITY | Sep 10, 2026, 11:32 AM UTC
L
HELP - Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
HELP - Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
Cybin Chief Growth Officer buys 100,000 shares for $1,178,280
Paul Glavine, an officer serving as Chief Growth Officer, purchased 100,000 Cybin common shares at $11.7828 per share for a total purchase amount of $1,178,280. The filing reports the acquisition was made directly, with
EQUITY | Sep 10, 2026, 10:20 AM UTC
L
Cybin officer Glavine Paul bought 90,000 shares for $1,042,677
Glavine Paul, Chief Growth Officer, purchased 90,000 Cybin common shares at a weighted average price of $11.5853 per share for a total purchase amount of $1,042,677. Following the transaction, Glavine Paul directly owned
EQUITY | Sep 09, 2026, 09:55 PM UTC
L
Cybin stake disclosed via Schedule 13D by Paul Glavine
Paul Glavine disclosed a 5.8% beneficial stake in Cybin Inc. in a Schedule 13D filing on September 9, 2026, following an August 31 open-market purchase of 90,000 shares and a September 1 grant of 1,046,899 restricted sto
EQUITY | Sep 09, 2026, 03:18 PM UTC
L
Helus Pharma CEO to participate in fireside chat Sept. 14
CEO Michael Halstead will take part in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT.
EQUITY | Sep 09, 2026, 11:32 AM UTC
L
Helus Pharma to participate in H.C. Wainwright global conference
Helus Pharma (HELP) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York.
EQUITY | Sep 09, 2026, 11:30 AM UTC
L
Helus Pharma CEO Halstead to speak at Cantor Global Healthcare Conf
Helus Pharma says CEO Michael Halstead will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Friday, Sept. 11, 2026 at 8:00 a.m. EDT.
EQUITY | Sep 03, 2026, 11:38 AM UTC
L
HELP - Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
HELP - Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
EQUITY | Sep 03, 2026, 11:30 AM UTC
L
HELP price target raised to $62 at TDCowen
Hammerstone MarketTalk reports TDCowen raised its price target for HELP from $8 to $62 and maintains a Buy rating.
EQUITY | Aug 20, 2026, 12:37 PM UTC
L
Helus Pharma appoints Regina Donohue as Chief People Officer
Helus Pharma (HELP) appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board.
EQUITY | Aug 18, 2026, 11:30 AM UTC
H
Helus Pharma reports Q1 fiscal 2027 financial results
Helus Pharma (HELP) reports first quarter fiscal 2027 financial results and recent business highlights.
EQUITY | Aug 14, 2026, 11:28 AM UTC
H
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ: AIRS ) fell sharply in pre-market trading following second-quarter results. Ai
EARNINGS | Aug 10, 2026, 12:02 PM UTC
M
Helus Pharma Appoints CEO
Helus Pharma names new CEO
EQUITY | Aug 03, 2026, 11:40 AM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
HELP initiated with an Overweight at Wells Fargo. PT $16
HELP initiated with an Overweight at Wells Fargo. PT $16
EQUITY | Jul 27, 2026, 10:22 AM UTC
H
Crude Oil Surges 2%; 3M Shares Gain After Q2 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 350 points on Tuesday. The Dow traded up 0.70% to 52,204.49 while the NASDAQ climbed 1.30% to 25,838.45. The S&P 500 also rose, gain
RATES | Jul 21, 2026, 06:18 PM UTC
H
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Nasdaq Composite falling around 150 points on Thursday. Shares of Abbott Laboratories (NYSE: ABT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 16, 2026, 02:11 PM UTC
H
FDA announces availability of final guidance for psychedelic drug research
The agency said,...
EARNINGS | Jul 15, 2026, 03:12 PM UTC
H
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
Jefferies notes that on...
EQUITY | Jul 13, 2026, 05:12 PM UTC
L
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPORTS SIX-MONTH DATA FROM COMP006 TRIAL:
EQUITY | Jul 09, 2026, 01:49 PM UTC
L
Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ: HELP ) with a Buy and lowers the price target from $45 to $42.
EQUITY | Jul 01, 2026, 01:29 PM UTC
H
CMPS: Depression Drug 86% Through Phase 3
CMPS' breakthrough-designated depression drug is 86% through its Phase 3 with topline data due this year
EQUITY | Jun 26, 2026, 01:31 PM UTC
M
12 Health Care Stocks Move
Multiple health care stocks are moving in Thursday's intraday session, with gainers including Atlantic International and SELLAS Life Sciences, and losers including Nano X Imaging and Passage Bio
EQUITY | Jun 25, 2026, 05:05 PM UTC
M
HELP Raises $50M
Helus Pharma announces closing of US$50 million underwritten offering
EQUITY | Jun 25, 2026, 01:28 PM UTC
M
HELP: Prices Offering
Helus Pharma prices underwritten offering of 10.3M shares at $4.85 per share and announces progress in clinical trial enrollment
EARNINGS | Jun 24, 2026, 10:08 AM UTC
M
HELP Prices $50M Offering
HELP prices $50M offering at $4.85/share
EQUITY | Jun 24, 2026, 10:04 AM UTC
M
HELP: Announces $50M Offering
Helus Pharma announces a US$50 million underwritten offering
EQUITY | Jun 24, 2026, 10:01 AM UTC
L
HELP Updates Trial Enrollment
Helus Pharma provides update on APPROACH Phase 3 trial enrollment progress
EARNINGS | Jun 24, 2026, 10:00 AM UTC
L
IBM AND OPENAI EXPAND CYBERSECURITY COLLABORATION, BRINGING FRONTIER AI CAPABILITIES TO HELP ENTERPRISES DEFEND AGAINST MACHINE-SPEED CYBER
IBM AND OPENAI EXPAND CYBERSECURITY COLLABORATION, BRINGING FRONTIER AI CAPABILITIES TO HELP ENTERPRISES DEFEND AGAINST MACHINE-SPEED CYBER THREATS.
EQUITY | Jun 22, 2026, 08:30 PM UTC